secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001104659-24-111027
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months
--------------------------------------------------------------------------------

- APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.
- Near-complete pSTAT6 inhibition and sustained TARC suppression observed up to 9 months after a single dose.
- No serious adverse events; treatment-emergent AEs were mild-to-moderate and unrelated to study drug.
- Phase 2 proof-of-concept data in moderate-to-severe AD expected in 2H 2025.
- Company plans R&D Day on December 2, 2024 to update on APG777 and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/0001104659-24-111027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/tm2426705d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-111027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer